相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The efficacy and safety of roxadustat treatment for anemia in patients with kidney disease: a meta-analysis and systematic review
Suhui Qie et al.
INTERNATIONAL UROLOGY AND NEPHROLOGY (2021)
Safety and Efficacy of Roxadustat for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis and Trial Sequential Analysis
Chao Liu et al.
FRONTIERS IN MEDICINE (2021)
Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan
Tadao Akizawa et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2020)
A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naive Chronic Kidney Disease Patients Not on Dialysis
Tadao Akizawa et al.
NEPHRON (2020)
Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial
Tadao Akizawa et al.
ADVANCES IN THERAPY (2019)
Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis
N. Chen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis
N. Chen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Prevalence, treatment patterns, and healthcare resource utilization in Medicare and commercially insured non-dialysis-dependent chronic kidney disease patients with and without anemia in the United States
Wendy L. St Peter et al.
BMC NEPHROLOGY (2018)
Anemia as a risk factor for all-cause mortality: obscure synergic effect of chronic kidney disease
Yuji Sato et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2018)
Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China
Nan Chen et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2017)
Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients
Anatole Besarab et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)
HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond
Patrick H. Maxwell et al.
NATURE REVIEWS NEPHROLOGY (2016)
Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6-to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study
Robert Provenzano et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2016)
Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients
Anatole Besarab et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2015)
Regulation of erythropoiesis by hypoxia-inducible factors
Volker H. Haase
BLOOD REVIEWS (2013)
The development of anemia is associated to poor prognosis in NKF/KDOQI stage 3 chronic kidney disease
Jose Portoles et al.
BMC NEPHROLOGY (2013)
Factors Related to the Absence of Anemia in Hemodialysis Patients
Ursula Verdalles et al.
BLOOD PURIFICATION (2011)
Chronic kidney disease is prevalent in Chinese patients admitted with verified cerebrovascular lesions and predicts short-term prognosis
Jing Xu et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2011)
Determinants of Hepcidin in Patients on Maintenance Hemodialysis: Role of Inflammation
Takahiro Kuragano et al.
AMERICAN JOURNAL OF NEPHROLOGY (2010)
Quantifying heterogeneity in a meta-analysis
JPT Higgins et al.
STATISTICS IN MEDICINE (2002)
Mortality, malnutrition, and atherosclerosis in ESRD:: What is the role of interleukin-6?
P Stenvinkel et al.
KIDNEY INTERNATIONAL (2002)
分享论文
